Pharmalittle: We're reading about Sanofi eyeing Insmed, AI speeding drug development, and more
AI cuts early-stage drug development time by up to 50% at top pharma firms, moving beyond admin into molecular design.
- 01Scientists at Bristol Myers Squibb, Novartis, Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca report AI is now driving molecule design, candidate prioritization, and safety screening—cutting early-stage development time by as much as half.
- 02The shift signals pharma's AI investment is graduating from back-office automation to core R&D.
- 03Separately, several major drugmakers told a House committee they will not open new clinical trial sites in China's Xinjiang region or at military-affiliated hospitals.
AI cuts early-stage drug development time by up to 50% at top pharma firms, moving beyond admin into molecular design.
Scientists at Bristol Myers Squibb, Novartis, Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca report AI is now driving molecule design, candidate prioritization, and safety screening—cutting early-stage development time by as much as half. The shift signals pharma's AI investment is graduating from back-office automation to core R&D. Separately, several major drugmakers told a House committee they will not open new clinical trial sites in China's Xinjiang region or at military-affiliated hospitals.
Watch: how pharma's AI-driven R&D compression reshapes CRO and life-sciences consulting workloads, pricing, and talent demand for computational biology specialists.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest.
Read the full article at statnews.comShow the full text · 2 min readHide the full text
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading, escort Mrs. Pharmalot to a musical event, and promenade with the official mascot. We also plan to hold another listening party, where the rotation will likely include this , this , this , this and this . And what about you? As noted previously, this remains a fine time to enjoy the great outdoors — perhaps a drive in the country is in order or a long walk by a lake or ocean. If the weather fails to cooperate, you could take in a moving picture show. Or maybe this is an opportunity to boost your local economy with a holiday purchase. Speaking of holidays, we will be off next week but never fear, a team of pinch hitters will be on hand. Meanwhile, whatever you do over the next 10 days or so, we hope you do something smashing. But be safe. Enjoy, and see you soon… Artificial intelligence has sped early-stage drug development work at some of the world’s largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic , Reuters explains. The top scientists at Bristol Myers Squibb, Novartis, Eli Lilly, Sanofi, Novo Nordisk and AstraZeneca all say they have moved beyond less glamorous tasks for AI like preparing regulatory filings. They are now using the technology for designing molecules, sorting out the most promising ones, and identifying safety risks. A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military , STAT writes. The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country. Continue to STAT+ to read the full story…
Don't miss tomorrow's
The Daily Pulse in your inbox each morning — sourced and linked.
CFO Peer Benchmarks
Margins, FCF conversion, ROIC, and the working-capital cycle (DSO/DPO/DIO/CCC), percentile-ranked against sector peers.
Executive Briefing
Assemble a company-specific, persona-framed executive deck from the site's own intelligence.
Ask KokoAI about Life Sciences & Healthcare
Cited answers across news, vendors & capabilities.